Trial Profile
A first-in-man, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial to evaluate the safety, tolerability and pharmacokinetics of oral semaglutide in healthy males receiving oral semaglutide
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2017
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man; Pharmacokinetics
- 18 Jul 2017 New trial record
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association